


Q
758136
M6

JOURNAL OF Clinical Microbiology

JCM



EBLING LIBRARY
UNIVERSITY OF WISCONSIN
JUL 21 2004
750 Highland Avenue
Madison, WI 53705

Published Monthly by the
**American Society
for Microbiology**



JULY 2004, VOLUME 42, NUMBER 7

Andrew B. Onderdonk, *Editor in Chief* (2009)
Channing Laboratory

Carole A. Bolin, *Editor* (2009)
Michigan State University

Richard T. D'Aquila, *Editor* (2006)
Vanderbilt University Medical Center

Gary V. Doern, *Editor* (2009)
University of Iowa Hospitals and Clinics

Michael M. Dunne, Jr., *Editor* (2009)
Washington University School of Medicine

Bradley W. Fenwick, *Editor* (2008)
Virginia Tech

Howard A. Fields, *Editor* (2005)
Centers for Disease Control and Prevention

Wendy M. Johnson, *Editor* (2007)
Cangene Corporation

Geoffrey A. Land, *Editor* (2009)
The Methodist Hospital

Stephen A. Moser, *Editor* (2009)
University of Alabama at Birmingham

Yi-Wei Tang, *Editor* (2006)
Vanderbilt University Medical Center

EDITORIAL BOARD

Anton P. Andonov (2006)
Max Arens (2005)
Jaber Aslanzadeh (2005)
William W. Barrow (2004)
Bernard Beall (2004)
Laurent Belec (2005)
William H. Benjamin (2004)
Kathryn Bernard (2006)
Carolyn M. Black (2006)
Patrick Boerlin (2004)
Erik Boettger (2004)
Paul Bourbeau (2005)
Mary E. Brandt (2006)
Stephen M. Brecher (2005)
Jens Bukh (2005)
Felipe Cabello (2004)
Richard Calderone (2004)
Angela M. Caliendo (2004)
Rafael Cantón (2006)
Jose Campione-Piccardo (2004)
Elisabeth Carniel (2004)
Karen C. Carroll (2004)
Jeffrey E. Christensen (2004)
Clifford G. Clark (2005)
Richard B. Clark (2004)
Stuart C. Clarke (2006)
Jill E. Clarridge (2006)
Dennis J. Cleri (2005)
Diana R. Cundell (2005)
Erica M. D'Agata (2005)
Mary C. Davis (2004)
Mary L. Delaney (2006)
Phyllis Della-Latta (2004)
Daniel J. Diekema (2006)
Frances P. Downes (2004)
Michel E. M. Drancourt (2005)
Hubert P. Endtz (2005)
Mark C. Enright (2006)
Dean Erdman (2004)
Mark J. Espy (2004)
Jerome Etienne (2005)
Robert C. Fader (2006)

Mark Feitelson (2006)
Heinrich U. Feldmann (2006)
Thomas A. Ficht (2006)
Annette W. Fothergill (2006)
Alvin Fox (2006)
Guido Funke (2005)
Thomas R. Fritsche (2006)
Lynne S. Garcia (2005)
Patricia Garrett (2005)
Robert D. Garrison (2006)
Mary J. George (2006)
Frank Gibson (2005)
Curt A. Gleaves (2006)
Henry P. Godfrey (2006)
Swee Han Goh (2006)
Irene Gonzalez (2006)
Ann Griffen (2004)
Brigitte P. Griffith (2005)
Jeffrey K. Griffiths (2006)
Peter A. Gross (2005)
Phalguni Gupta (2004)
Gerri Hall (2005)
James L. Harris (2006)
Kevin C. Hazen (2004)
Klaus Hedman (2004)
T. Hong (2006)
Susan A. Howell (2006)
Henry Hsu (2006)
Johannes Huebner (2006)
Wendy A. Hutchins (2006)
Thomas J. Inzana (2004)
Brad Jett (2004)
Kai M. Kam (2005)
Sue C. Kehl (2006)
Yury E. Khudyakov (2006)
Deanna Kiska (2004)
Brent E. Korba (2006)
Mel Krajden (2006)
Vincent J. LaBombardi (2005)
Davise H. Larone (2004)
Brent A. Lasker (2004)
Albert J. Lastovica (2005)

Paul N. Levett (2005)
Michael H. Levi (2004)
Michael J. Loeffelholz (2005)
Judith Lovchik (2005)
Yvonne A. Lue (2006)
C. R. Madeley (2005)
Lawrence C. Madoff (2005)
Eshwar Mahenthalingam (2004)
Carl F. Marrs (2006)
Suzanne M. Matsui (2005)
Alexander J. McAdam (2005)
Dennis J. McCance (2005)
Yvette S. McCarter (2005)
M. Catherine McEllistrem (2006)
Chris Miller (2005)
Ellen A. S. Moland (2005)
Stephan S. Monroe (2004)
Lucy M. Mutharia (2006)
Irving Nachamkin (2004)
Gopinath B. Nair (2004)
Jim Newell (2004)
Christopher W. Olsen (2006)
Arvind A. Padhye (2004)
Preeti K. Pancholi (2006)
Lawrence C. Paoletti (2004)
Christopher J. Papsian (2004)
Jean B. Patel (2006)
Pravin H. Patel (2006)
Robin Patel (2004)
Charles S. Pavia (2005)
Ellena Peterson (2004)
Lance Peterson (2005)
Astrid K. Petrich (2006)
Michael A. Pfaller (2006)
David H. Pincus (2006)
Tyrone L. Pitt (2006)
Xuan Qin (2006)
Rama Ramani (2004)
Didier Raoult (2004)
Patricia S. Reichelderfer (2005)
Andrew Reilly (2004)

Jurgen A. Richt (2006)
Sandra S. Richter (2006)
William H. Riley (2005)
Kathryn L. Ruoff (2006)
Pekka I. A. Saikku (2004)
Robert L. Sautter (2004)
D. Scott Schmid (2006)
Ira Schwartz (2005)
David L. Sewell (2004)
Daniel S. Shapiro (2005)
Prem L. Sharma (2005)
Virginia D. Shortridge (2005)
Sanjay K. Shukla (2005)
Thomas F. Smith (2006)
Stephen A. Spector (2004)
Alain C. Stinzi (2005)
Charles W. Stratton (2005)
Deanna A. Sutton (2005)
Ella M. Swierkosz (2004)
Sam R. Telford III (2006)
Raymond Tellier (2005)
Richard M. Thorn (2005)
Graham Tipples (2006)
Francesca Torriani (2005)
Gregory J. Tyrrell (2006)
Lucio Vera-Cabrera (2006)
Elizabeth A. Wagar (2004)
Ken B. Waites (2005)
Thomas J. Walsh (2004)
Yun W. Wang (2006)
Audrey Wanger (2005)
David W. Warnock (2004)
David F. Welch (2005)
Robbin S. Weyant (2004)
Susan Whittier (2004)
Patricia P. Wilkins (2005)
Marianna Wilson (2006)
Patricia L. Winokur (2006)
Frank G. Witebsky (2004)
Donna M. Wolk (2006)
Gail L. Woods (2004)
Xiaotian Zheng (2005)

Samuel Kaplan, *Chairman, Publications Board* **Linda M. Illig**, *Director, Journals*
Anastacia Thomasian, *Production Editor*

The *Journal of Clinical Microbiology* (ISSN 0095-1137), a publication of the American Society for Microbiology (ASM), 1752 N St., N.W., Washington, DC 20036-2904, is devoted to the dissemination of new knowledge concerning the applied microbiological aspects of human and animal infections and infestations, particularly regarding their etiologic agents, diagnosis, and epidemiology. Papers dealing with antibiotics and antimicrobial agents and chemotherapy, with fundamental aspects of infection and immunity, and with food or dairy microbiology fall within the scope of other ASM publications. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Journals Department. The *Journal* is published monthly, one volume per year. Nonmember print subscription prices (per year) are: \$432, U.S.; \$460, Canada (plus 7% GST, or 7% GST + 8% HST where applicable); \$499, Europe; \$522, Latin America; \$526, rest of world. Member print subscription prices (per year) are: \$62, U.S.; \$89, Canada (plus 7% GST, or 7% GST + 8% HST where applicable); \$127, Europe; \$149, Latin America; \$153, rest of world. Single copies are: \$50, nonmember; \$25, member (Canadians add 7% GST, or 7% GST + 8% HST where applicable). For prices of electronic versions, contact the Subscriptions Unit, ASM. Correspondence relating to subscriptions, defective copies, missing issues, and availability of back issues should be directed to the Subscriptions Unit, ASM; correspondence relating to reprint orders should be directed to the Reprint Order Unit, ASM; and correspondence relating to disposition of submitted manuscripts, proofs, and general editorial matters should be directed to the Journals Department, American Society for Microbiology, 1752 N St., N.W., Washington, DC 20036-2904. Phone: (202) 737-3600.

Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed.

Periodicals postage paid at Washington, DC 20036, and at additional mailing offices.

POSTMASTER: Send address changes to *Journal of Clinical Microbiology*, ASM, 1752 N St., N.W., Washington, DC 20036-2904.

Made in the United States of America. Printed on acid-free paper.

DOI: 10.1128/JCM.42.7.2004 CODEN: JCMIDW

Copyright © 2004, American Society for Microbiology. All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

EBLING LIBRARY
UNIVERSITY OF WISCONSIN
JUL 2 1 2004

750 Highland Avenue
Madison, WI 53705

MINIREVIEW

Rapid Detection of Antimicrobial-Resistant Organism Carriage: an Unmet Clinical Need

Daniel J. Diekema, Kirsty J. Dodgson, Bryndis Sigurdardottir, and Michael A. Pfaller 2879–2883

BACTERIOLOGY

Bacteremia in an Immunocompromised Patient Caused by a Commensal *Neisseria meningitidis* Strain Harboring the Capsule Null Locus (*cnt*)

Ulrich Vogel, Heike Claus, Lutz von Müller, Donald Bunjes, Johannes Elias, and Matthias Frosch 2898–2901

Molecular Characterization of Extended-Spectrum Beta-Lactamases Produced by Clinical Isolates of *Klebsiella pneumoniae* and *Escherichia coli* from a Korean Nationwide Survey

Seok Hoon Jeong, Il Kwon Bae, Jung Hun Lee, Seung Ghyu Sohn, Geun Ho Kang, Ghil Ja Jeon, Young Ho Kim, Byeong Chul Jeong, and Sang Hee Lee 2902–2906

Prospective Study of a Real-Time PCR That Is Highly Sensitive, Specific, and Clinically Useful for Diagnosis of Meningococcal Disease in Children

Penelope A. Bryant, Hua Yi Li, Angelo Zaia, Julia Griffith, Geoff Hogg, Nigel Curtis, and Jonathan R. Carapetis 2919–2925

Molecular Typing of *Neisseria gonorrhoeae* Isolates by Pyrosequencing of Highly Polymorphic Segments of the *porB* Gene

Magnus Unemo, Per Olcén, Jon Jonasson, and Hans Fredlund 2926–2934

Isolation of Recombinant Antibodies against EspA and Intimin of *Escherichia coli* O157:H7

Sarah A. Kühne, William S. Hawes, Roberto M. La Ragione, Martin J. Woodward, Garry C. Whitlam, and Kevin C. Gough 2966–2976

Use of Robotized DNA Isolation and Real-Time PCR To Quantify and Identify Close Correlation between Levels of *Neisseria meningitidis* DNA and Lipopolysaccharides in Plasma and Cerebrospinal Fluid from Patients with Systemic Meningococcal Disease

Reidun Øvstebø, Petter Brandtzaeg, Berit Brusletto, Kari Bente Foss Haug, Knut Lande, Ernst Arne Høyby, and Peter Kierulf 2980–2987

Molecular Analysis of the Microflora Associated with Dental Caries

M. A. Munson, A. Banerjee, T. F. Watson, and W. G. Wade 3023–3029

Studies on the Involvement of the Exopolysaccharide Produced by Cystic Fibrosis-Associated Isolates of the *Burkholderia cepacia* Complex in Biofilm Formation and in Persistence of Respiratory Infections

Mónica V. Cunha, Sílvia A. Sousa, Jorge H. Leitão, Leonilde M. Moreira, Paula A. Videira, and Isabel Sá-Correia 3052–3058

Prevalence of the *hifBC*, *hmw1A*, *hmw2A*, *hmwC*, and *hia* Genes in *Haemophilus influenzae* Isolates

I. Zafer Ecevit, Kirk W. McCrea, Melinda M. Pettigrew, Ananda Sen, Carl F. Marrs, and Janet R. Gilsdorf 3065–3072

Use of In Vivo-Generated Biofilms from Hemodialysis Catheters To Test the Efficacy of a Novel Antimicrobial Catheter Lock for Biofilm Eradication In Vitro

P. Kite, K. Eastwood, S. Sugden, and S. L. Percival 3073–3076

Comparison of the APTIMA CT and GC Assays with the APTIMA Combo 2 Assay, the Abbott LCx Assay, and Direct Fluorescent-Antibody and Culture Assays for Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*

B. Boyadzhyan, T. Yashina, J. H. Yatabe, M. Patnaik, and C. S. Hill 3089–3093

Continued on following page

Endemic, Epidemic Clone of <i>Salmonella enterica</i> Serovar Typhi Harboring a Single Multidrug-Resistant Plasmid in Vietnam between 1995 and 2002	Thi Anh Hong Le, Monique Lejay-Collin, Patrick A. D. Grimont, Thuy Long Hoang, Thi Vinh Nguyen, Francine Grimont, and Maurice R. Scavizzi	3094–3099
Quantitative Analysis of Diverse <i>Lactobacillus</i> Species Present in Advanced Dental Caries	Roy Byun, Mangala A. Nadkarni, Kim-Ly Chhour, F. Elizabeth Martin, Nicholas A. Jacques, and Neil Hunter	3128–3136
Evaluation of the Hyplex BloodScreen Multiplex PCR–Enzyme-Linked Immunosorbent Assay System for Direct Identification of Gram-Positive Cocci and Gram-Negative Bacilli from Positive Blood Cultures	Nele Wellinghausen, Beate Wirths, Andreas Essig, and Lars Wassill	3147–3152
Multiplex Real-Time PCR for Detection of <i>Anaplasma phagocytophilum</i> and <i>Borrelia burgdorferi</i>	Joshua W. Courtney, Leah M. Kostelnik, Nordin S. Zeidner, and Robert F. Massung	3164–3168
Use of Swabs without Transport Media for the Gen-Probe Group A Strep Direct Test	Paul P. Bourbeau and Barbara J. Heiter	3207–3211
Use of Applied Biosystems 7900HT Sequence Detection System and Taqman Assay for Detection of Quinolone-Resistant <i>Neisseria gonorrhoeae</i>	Julie Giles, Justin Hardick, Jeffrey Yuenger, Michael Dan, Karl Reich, and Jonathan Zenilman	3281–3283
Detailed Protocol for Purification of <i>Chlamydia pneumoniae</i> Elementary Bodies	Sanghamitra Mukhopadhyay, Alejandra P. Clark, Erin D. Sullivan, Richard D. Miller, and James T. Summersgill	3288–3290
Performance of the MagNA Pure LC Robot for Extraction of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> DNA from Urine and Swab Specimens	Nicholas Dalesio, Vince Marsiglia, Andrew Quinn, Thomas C. Quinn, and Charlotte A. Gaydos	3300–3302
Phenotypic and Molecular Characterization of Erythromycin Resistance in Four Isolates of <i>Streptococcus</i>-Like Gram-Positive Cocci Causing Bacteremia	Patrick C. Y. Woo, Amanda P. C. To, Susanna K. P. Lau, Ami M. Y. Fung, and Kwok-yung Yuen	3303–3305
A Novel Multiplex Real-Time PCR Assay for Rapid Typing of Major Staphylococcal Cassette Chromosome <i>mec</i> Elements	Patrice Francois, Gesuele Renzi, Didier Pittet, Manuela Bento, Daniel Lew, Stephan Harbarth, Pierre Vaudaux, and Jacques Schrenzel	3309–3312
Genetic Relatedness and Quinolone Resistance of <i>Campylobacter jejuni</i> Strains Isolated in 2002 in Hong Kong	Yiu-Wai Chu, Man-Yu Chu, Kit-Yee Luey, Yin-Wa Ngan, Ka-Lok Tsang, and Kai-Man Kam	3321–3323
Epidemiological Investigation of Bloodstream Infections by Extended-Spectrum Cephalosporin-Resistant <i>Escherichia coli</i> in a Taiwanese Teaching Hospital	Jing-Jou Yan, Wen-Chien Ko, Jiunn-Jong Wu, Shu-Huei Tsai, and Chin-Luan Chuang	3329–3332
Diagnostic Utility and Clinical Significance of Naso- and Oropharyngeal Samples Used in a PCR Assay To Diagnose <i>Mycoplasma pneumoniae</i> Infection in Children with Community-Acquired Pneumonia	Ian C. Michelow, Kurt Olsen, Juanita Lozano, Lynn B. Duffy, George H. McCracken, and R. Doug Hardy	3339–3341
Differences in Clinical Manifestation of <i>Streptococcus pneumoniae</i> Infection Are Not Correlated with In Vitro Production and Release of the Virulence Factors Pneumolysin and Lipoteichoic and Teichoic Acids	Annette Spreer, Astrid Lis, Joachim Gerber, Ralf René Reinert, Helmut Eiffert, and Roland Nau	3342–3345
Evaluation of Indirect Fluorescence Antibody Assay for Detection of <i>Bartonella clarridgeiae</i> and Seroprevalence of <i>B. clarridgeiae</i> among Patients with Suspected Cat Scratch Disease	Hidehiro Tsuneoka, Akiko Umeda, Masato Tsukahara, and Kohsuke Sasaki	3346–3349
Clinical and Microbiological Analysis of Bloodstream Infections Caused by <i>Chryseobacterium meningosepticum</i> in Nonneonatal Patients	Pen-Yi Lin, Chishih Chu, Lin-Hui Su, Chung-Tsui Huang, Wen-Ya Chang, and Cheng-Hsun Chiu	3353–3355

Continued on following page

Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used

T. R. Andereg, R. N. Jones, H. S. Sader, and the Quality Control Working Group 3356-3358

CHLAMYDIOLOGY AND RICKETTSIOLOGY

Combination of PCR Targeting the VD2 of *omp1* and Reverse Line Blot Analysis for Typing of Urogenital *Chlamydia trachomatis* Serovars in Cervical Scrape Specimens

Monica Molano, Chris J. L. M. Meijer, Servaas A. Morré, Rene Pol, and Adriaan J. C. van den Brule 2935-2939

Comparison of Three Nucleic Acid Amplification Tests for Detection of *Chlamydia trachomatis* in Urine Specimens

Charlotte A. Gaydos, Mellisa Theodore, Nicholas Dalesio, Billie Jo Wood, and Thomas C. Quinn 3041-3045

Immunohistostaining Assays for Detection of *Chlamydia pneumoniae* in Atherosclerotic Arteries Indicate Cross-Reactions with Nonchlamydial Plaque Constituents

Vicky Y. Hoymans, Johan M. Bosmans, Dominique Ursi, Wim Martinet, Floris L. Wuyts, Eric Van Marck, Martin Altwegg, Christiaan J. Vrints, and Margareta M. Ieven 3219-3224

MYCOBACTERIOLOGY AND AEROBIC ACTINOMYCETES

High-Throughput Method for Detecting Genomic-Deletion Polymorphisms

Yves-Olivier Luc Goguet de la Salmonière, C. C. Kim, A. G. Tsolaki, A. S. Pym, M. S. Siegrist, and Peter M. Small 2913-2918

Molecular Epidemiology of Tuberculosis among Immigrants in Hamburg, Germany

Roland Diel, Sabine Rüsç-Gerdes, and Stefan Niemann 2952-2960

Assessment of Partial Sequencing of the 65-Kilodalton Heat Shock Protein Gene (*hsp65*) for Routine Identification of *Mycobacterium* Species Isolated from Clinical Sources

Alan McNabb, Diane Eisler, Kathy Adie, Marie Amos, Mabel Rodrigues, Gwen Stephens, William A. Black, and Judith Isaac-Renton 3000-3011

Improved Sensitivity of Nucleic Acid Amplification for Rapid Diagnosis of Tuberculous Meningitis

Isik Somuncu Johansen, Bettina Lundgren, Fehmi Tabak, Björn Petrini, Salih Hosoglu, Nese Saltoglu, and Vibeke Østergaard Thomsen 3036-3040

Comparative Evaluation of the New Version of the INNO-LiPA Mycobacteria and GenoType Mycobacterium Assays for Identification of *Mycobacterium* Species from MB/BacT Liquid Cultures Artificially Inoculated with Mycobacterial Strains

Eduardo Padilla, Victoria González, Jose María Manterola, Andrés Pérez, María Dolores Quesada, Sergio Gordillo, Cristina Vilaplana, María Angeles Pallarés, Sonia Molinos, María Dolores Sánchez, and Vicente Ausina 3083-3088

Antigenic Evidence of Prevalence and Diversity of *Mycobacterium tuberculosis* Arabinomannan

Aharona Glatman-Freedman, Arturo Casadevall, Zongdong Dai, William R. Jacobs, Jr., Anping Li, Sheldon L. Morris, Josepine Anne D. Navoa, Sajida Piperdi, John B. Robbins, Rachel Schneerson, J. Reid Schwebach, and Michael Shapiro 3225-3231

- Molecular Genotyping of a Large, Multicentric Collection of Tubercle Bacilli Indicates Geographical Partitioning of Strain Variation and Has Implications for Global Epidemiology of *Mycobacterium tuberculosis*** Niyaz Ahmed, Mahfooz Alam, K. Rajender Rao, Farhana Kauser, N. Ashok Kumar, Nazia N. Qazi, Vartul Sangal, V. D. Sharma, Ram Das, V. M. Katoch, K. J. R. Murthy, Sujai Suneetha, S. K. Sharma, Leonardo A. Sechi, Robert H. Gilman, and Seyed E. Hasnain 3240–3247
- High Genetic Diversity Revealed by Variable-Number Tandem Repeat Genotyping and Analysis of *hsp65* Gene Polymorphism in a Large Collection of “*Mycobacterium canettii*” Strains Indicates that the *M. tuberculosis* Complex Is a Recently Emerged Clone of “*M. canettii*”** Michel Fabre, Jean-Louis Koeck, Philippe Le Flèche, Fabrice Simon, Vincent Hervé, Gilles Vergnaud, and Christine Pourcel 3248–3255
- LightCycler-Based Differentiation of *Mycobacterium abscessus* and *Mycobacterium chelonae*** L. Sedlacek, M. Rifai, K. Feldmann, and F. C. Bange 3284–3287
- Application of Oxidation-Reduction Assay for Monitoring Treatment of Patients with Pulmonary Tuberculosis** Parissa Farnia, Foroazan Mohammadi, Mehdi Mirsaedi, Abolhasan Zia Zarife, Javad Tabatabaee, Katayoon Bahadori, Muslem Bahadori, Mohammad Reza Masjedi, and Ali Akbar Velayati 3324–3325
- Direct Identification of *Mycobacterium haemophilum* in Skin Lesions of Immunocompromised Patients by PCR-Restriction Endonuclease Analysis** S. X. Wang, L. H. Sng, H. N. Leong, and B. H. Tan 3336–3338

MYCOLOGY

- Intra- and Interlaboratory Study of a Method for Testing the Antifungal Susceptibilities of Dermatophytes** M. A. Ghannoum, V. Chaturvedi, A. Espinel-Ingroff, M. A. Pfaller, M. G. Rinaldi, W. Lee-Yang, and D. W. Warnock 2977–2979
- Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against *Candida* Species by Use of an International Collection of More than 3,000 Clinical Isolates** M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema 3117–3119
- Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of *Candida* spp.** M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema 3137–3141
- Geographic Variation in the Susceptibilities of Invasive Isolates of *Candida glabrata* to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002** M. A. Pfaller, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema 3142–3146
- Comparison of Different Methods of Isolation of DNA of Commonly Encountered *Candida* Species and Its Quantitation by Using a Real-Time PCR-Based Assay** Younes Maaroufi, Naïma Ahariz, Mireille Husson, and Françoise Crokaert 3159–3163
- Cloning and Characterization of *Trichophyton rubrum* Genes Encoding Actin, Tri r2, and Tri r4** Jimin Gao and Akira Takashima 3298–3299
- Detection of *Pneumocystis jiroveci* in Respiratory Specimens by Four Staining Methods** G. W. Procop, S. Haddad, J. Quinn, M. L. Wilson, N. G. Henshaw, L. B. Reller, R. L. Artymyshyn, M. T. Katanik, and M. P. Weinstein 3333–3335

Continued on following page

PARASITOLOGY

Performance of a New, Rapid Assay for Detection of *Trichomonas vaginalis*

Ann Kurth, William L. H. Whittington, Matthew R. Golden, Katherine K. Thomas, King K. Holmes, and Jane R. Schwebke 2940–2943

Risk Factors for Sporadic Cryptosporidiosis among Immunocompetent Persons in the United States from 1999 to 2001

Sharon L. Roy, Stephanie M. DeLong, Sara A. Stenzel, Beletshachew Shiferaw, Jacquelin M. Roberts, Asheena Khalakdina, Ruthanne Marcus, Suzanne D. Segler, Dipti D. Shah, Stephanie Thomas, Duc J. Vugia, Shelley M. Zansky, Vance Dietz, Michael J. Beach, and the Emerging Infections Program FoodNet Working Group 2944–2951

Purification of *Enterocytozoon bienersi* Spores from Stool Specimens by Gradient and Cell Sorting Techniques

Zuzana Kucerova, Hercules Moura, Gordon J. Leitch, Rama Sriram, Caryn Bern, Vivian Kawai, Daniel Vargas, Robert H. Gilman, Eduardo Ticona, Aldo Vivar, and Govinda S. Visvesvara 3256–3261

Detection and Genotyping of *Entamoeba histolytica*, *Entamoeba dispar*, *Giardia lamblia*, and *Cryptosporidium parvum* by Oligonucleotide Microarray

Zheng Wang, Gary J. Vora, and David A. Stenger 3262–3271

Real-Time PCR Assay for Detection and Genotype Differentiation of *Giardia lamblia* in Stool Specimens

Rebecca A. Guy, Chongxie Xiao, and Paul A. Horgen 3317–3320

Use of Two Sensitive and Specific Immunoblot Markers, Em70 and Em90, for Diagnosis of Alveolar Echinococcosis

Metin Korkmaz, Tonay Inceboz, Fehmi Celebi, Aylin Babaoglu, and Ahmet Uner 3350–3352

VIROLOGY

Detection of Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in SARS Patients by Enzyme-Linked Immunosorbent Assay

Susanna K. P. Lau, Patrick C. Y. Woo, Beatrice H. L. Wong, Hoi-Wah Tsoi, Gibson K. S. Woo, Rosana W. S. Poon, Kwok-Hung Chan, William I. Wei, J. S. Malik Peiris, and Kwok-Yung Yuen 2884–2889

Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays

R. Gonzalez, B. Masquelier, H. Fleury, B. Lacroix, A. Troesch, G. Vernet, and J. N. Telles 2907–2912

Performance of Commercially Available Enzyme Immunoassays for Detection of Antibodies against Herpes Simplex Virus Type 2 in African Populations

Eddy Van Dyck, Anne Buvé, Helen A. Weiss, Judith R. Glynn, David W. G. Brown, Bénédicte De Deken, John Parry, and Richard J. Hayes 2961–2965

Coexistence of Multiple Genotypes, Including Newly Identified Genotypes, in Outbreaks of Gastroenteritis Due to *Norovirus* in Japan

Tsutomu Kageyama, Michiyo Shinohara, Kazue Uchida, Shuetsu Fukushi, Fuminori B. Hoshino, Shigeyuki Kojima, Reiko Takai, Tomoichiro Oka, Naokazu Takeda, and Kazuhiko Katayama 2988–2995

Evaluation of the Binax NOW, BD Directigen, and BD Directigen EZ Assays for Detection of Respiratory Syncytial Virus

Marilyn J. Ohm-Smith, Patricia S. Nassos, and Barbara L. Haller 2996–2999

Dissociation of Serum and Liver Hepatitis C Virus RNA Levels in Patients Coinfected with Human Immunodeficiency Virus and Treated with Antiretroviral Drugs	Milena Furione, Renato Maserati, Marta Gatti, Fausto Baldanti, Agostino Cividini, Raffaele Bruno, Giuseppe Gerna, and Mario U. Mondelli	3012–3016
Measles Virus Genotyping by Nucleotide-Specific Multiplex PCR	Jacques R. Kremer, Fred Fack, Christophe M. Olinger, Mick N. Mulders, Claude P. Muller	3017–3022
High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002	Cécile Henquell, Carole Cartau, Armand Abergel, Henri Laurichesse, Christel Regagnon, Christophe De Champs, Jean-Luc Bailly, and Hélène Peigue-Lafeuille	3030–3035
Highly Sensitive Assay for Detection of Enterovirus in Clinical Specimens by Reverse Transcription-PCR with an Armored RNA Internal Control	Marcel Beld, René Minnaar, Jan Weel, Cees Sol, Marjolein Damen, Harry van der Avoort, Pauline Wertheim-van Dillen, Alex van Breda, and René Boom	3059–3064
Simultaneous Runs of the Bayer VERSANT HIV-1 Version 3.0 and HCV bDNA Version 3.0 Quantitative Assays on the System 340 Platform Provide Reliable Quantitation and Improved Work Flow	Tarek Elbeik, Norman Markowitz, Patricia Nassos, Uday Kumar, Scott Beringer, Barbara Haller, and Valerie Ng	3120–3127
Detection and Typing of Human Papillomavirus by E6 Nested Multiplex PCR	K. Sotlar, D. Diemer, A. Dethleffs, Y. Hack, A. Stubner, N. Vollmer, S. Menton, M. Menton, K. Dietz, D. Wallwiener, R. Kandolf, and B. Bültmann	3176–3184
Comparison of Three Commercially Available Serologic Assays Used To Detect Human Parvovirus B19-Specific Immunoglobulin M (IgM) and IgG Antibodies in Sera of Pregnant Women	Allyson R. Butchko and Jeanne A. Jordan	3191–3195
Discovery of Novel Human and Animal Cells Infected by the Severe Acute Respiratory Syndrome Coronavirus by Replication-Specific Multiplex Reverse Transcription-PCR	Laura Gillim-Ross, Jill Taylor, David R. Scholl, Jared Ridenour, Paul S. Masters, and David E. Wentworth	3196–3206
Amplicon Sequencing and Improved Detection of Human Rhinovirus in Respiratory Samples	Christelle Deffernez, Werner Wunderli, Yves Thomas, Sabine Yerly, Luc Perrin, and Laurent Kaiser	3212–3218
Use of Oligonucleotide Microarrays for Rapid Detection and Serotyping of Acute Respiratory Disease-Associated Adenoviruses	Baochuan Lin, Gary J. Vora, Dzung Thach, Elizabeth Walter, David Metzgar, Clark Tibbetts, and David A. Stenger	3232–3239
Development and Clinical Evaluation of a Highly Sensitive DNA Microarray for Detection and Genotyping of Human Papillomaviruses	TaeJeong Oh, ChangJin Kim, SukKyung Woo, TaeSeung Kim, DongJun Jeong, MyungSoon Kim, Sunwoo Lee, HyunSill Cho, and Sungwhan An	3272–3280
Identification of the Severe Acute Respiratory Syndrome Coronavirus by Simultaneous Multigene DNA Sequencing	T. Vinayagamoorthy, Kirk Mulatz, and Roger Hodgkinson	3291–3294
Influenza B Virus Victoria Group with a New Glycosylation Site Was Epidemic in Japan in the 2002-2003 Season	Naoko Nakagawa, Ritsuko Kubota, Akiko Maeda, and Yoshinobu Okuno	3295–3297
Genotypic Profile of Human Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus) in Urine	M. M. Beyari, T. A. Hodgson, W. Kondowe, E. M. Molyneux, C. M. Scully, S. R. Porter, and C. G. Teo	3313–3316
Evaluation of a Real-Time PCR Assay Using the LightCycler System for Detection of Parvovirus B19 DNA	Richard S. Buller and Gregory Storch	3326–3328

Continued on following page

CLINICAL VETERINARY MICROBIOLOGY

- Molecular and Ultrastructural Characterization of Porcine Hippurate-Negative *Brachyspira pilosicoli*** Marja Fossi, Tarja Pohjanvirta, Antti Sukura, Sirpa Heinikainen, Rikke Lindecrona, and Sinikka Pelkonen 3153–3158
- Multiplex PCR Assay for Detection of *Streptococcus suis* Species and Serotypes 2 and 1/2 in Tonsils of Live and Dead Pigs** C. Marois, S. Bougeard, M. Gottschalk, and M. Kobisch 3169–3175

EPIDEMIOLOGY

- Reference System for Characterization of *Bordetella pertussis* Pulsed-Field Gel Electrophoresis Profiles** Abdolreza Advani, Declan Donnelly, and Hans Hallander 2890–2897
- Molecular Epidemiology of *Mycobacterium tuberculosis* in Western Sweden** Karine Brudey, Max Gordon, Peter Moström, Liselott Svensson, Bodil Jonsson, Christophe Sola, Malin Ridell, and Nalin Rastogi 3046–3051
- Widespread Dissemination in The Netherlands of the Epidemic Berlin Methicillin-Resistant *Staphylococcus aureus* Clone with Low-Level Resistance to Oxacillin** W. J. B. Wannet, E. Spalburg, M. E. O. C. Heck, G. N. Pluister, R. J. L. Willems, and A. J. de Neeling 3077–3082
- Clonal Relatedness of Enterotoxigenic *Escherichia coli* Strains Isolated from a Cohort of Young Children in Guinea-Bissau** Hans Steinsland, Palle Valentiner-Branth, Peter Aaby, Kåre Mølbak, and Halvor Sommerfelt 3100–3107
- Molecular Epidemiology of *Serratia marcescens* in Two Hospitals in Danzig, Poland, over a 5-Year Period** Łukasz Naumiuk, Anna Baraniak, Marek Gniadkowski, Beata Krawczyk, Bartosz Rybak, Ewa Sadowy, Alfred Samet, and Józef Kur 3108–3116
- Diversity among Community Isolates of Methicillin-Resistant *Staphylococcus aureus* in Australia** F. G. O'Brien, T. T. Lim, F. N. Chong, G. W. Coombs, M. C. Enright, D. A. Robinson, A. Monk, B. Saïd-Salim, B. N. Kreiswirth, and W. B. Grubb 3185–3190
- Serotypes and Genotypes of Erythromycin-Resistant Group B Streptococci in Korea** Young Uh, In Ho Jang, Gyu Yel Hwang, Mi Kyung Lee, Kap Jun Yoon, and Hyo Youl Kim 3306–3308
- Extended-Spectrum- β -Lactamase (TEM-52)-Producing Strains of *Salmonella enterica* of Various Serotypes Isolated in France** François-Xavier Weill, Marie Demartin, Laëtitia Fabre, and Patrick A. D. Grimont 3359–3362

CASE REPORTS

- Fungemia Caused by *Zygoascus hellenicus* in an Allogeneic Stem Cell Transplant Recipient** Mary E. Brandt, Carol A. Kauffman, Peter G. Pappas, Naureen Iqbal, Beth A. Arthington-Skaggs, Wendy Lee-Yang, and Maudy T. Smith 3363–3365
- First Comprehensively Documented Case of *Paracoccus yeii* Infection in a Human** Guido Funke, Reinhard Frodl, and Hartmut Sommer 3366–3368
- Septic Arthritis of the Knee Due to *Fusobacterium necrophorum*** Paresch D. Sonsale, Mark R. Philipson, and Jilean Bowskill 3369–3370
- Prosthetic Mitral Valve Endocarditis Due to *Ochrobactrum anthropi*: Case Report** M. P. Romero Gómez, A. M. Peinado Esteban, J. A. Sobrino Daza, J. A. Sáez Nieto, D. Alvarez, and P. Peña García 3371–3373

Bacteriology of a Bear Bite Wound to a Human: Case Report

Dennis Kunimoto, Robert Rennie,
Diane M. Citron, and Ellie J. C.
Goldstein

3374-3376

LETTERS TO THE EDITOR

***Legionella pneumophila* Serogroup 1 Antigen Can Be Detected in Sputum Samples by an Immunochromatographic Assay**

Kristoffer Strålin, Ingegerd
Alriksson, and Eva Törnqvist

3377

Human Tracheopulmonary Myiasis

Robert D. Garrison

3378

Internal Amplification Control for PCR Should Not Be Mandatory in the Clinical Medical Environment

Letter: Timothy Barkham.
Reply: Jeffrey Hoorfar

3379-3380

Cover photograph (Copyright © 2004, American Society for Microbiology. All Rights Reserved.): The organism shown was isolated from the blood of a 66-year-old man with a long history of refractory chronic lymphocytic leukemia. The patient presented with a fever of 105°F and rhinorrhea several days after completing a 6-week cycle of CamPath (anti-CD52) therapy. The patient's upper respiratory symptoms progressed to pneumonia (requiring assisted ventilation in the intensive care unit) and concomitant multiorgan failure. Ten days after presentation, a fungal blood isolator culture demonstrated a rare mold. The isolate was identified as *Histoplasma capsulatum* by morphology and conversion to yeast forms at 37°C. *H. capsulatum* was also isolated from bronchioalveolar lavage fluid, and rare yeast forms were noted upon bone marrow biopsy. The results of serum and urine immunoassays carried out at presentation were strongly positive for *Histoplasma* antigen. The patient improved dramatically upon receiving treatment with liposomal amphotericin B and was discharged after a 3-week hospital course. The micrograph shows the tuberculated macroconidia of *H. capsulatum* cultured at 30°C, stained with lactophenol blue.

Intra- and Interlaboratory Study of a Method for Testing the Antifungal Susceptibilities of Dermatophytes

M. A. Ghannoum,^{1*} V. Chaturvedi,² A. Espinel-Ingroff,³ M. A. Pfaller,⁴
M. G. Rinaldi,⁵ W. Lee-Yang,⁶ and D. W. Warnock⁶

Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio¹; Department of Health, State of New York, Albany, New York²; Medical College of Virginia/Virginia Commonwealth University, Richmond, Virginia³; Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa⁴; Laboratory Service, University of Texas Health Science Center, Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas⁵; and Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia⁶

Received 15 January 2004/Returned for modification 3 March 2004/Accepted 4 April 2004

The National Committee for Clinical Laboratory Standards (NCCLS) M38-A standard for the susceptibility testing of conidium-forming filamentous fungi does not explicitly address the testing of dermatophytes. This multicenter study, involving six laboratories, investigated the MIC reproducibility of seven antifungal agents tested against 25 dermatophyte isolates (5 blinded pairs of five dermatophyte species per site for a total of 300 tests), using the method of dermatophyte testing developed at the Center for Medical Mycology, Cleveland, Ohio. The dermatophytes tested included *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, *Epidermophyton floccosum*, and *Microsporum canis*. Seven antifungals with activity against dermatophytes were tested, including ciclopirox, fluconazole, griseofulvin, itraconazole, posaconazole, terbinafine, and voriconazole. Interlaboratory MICs for all isolates were in 92 to 100% agreement at a visual endpoint reading of 50% inhibition as compared to the growth control and 88 to 99% agreement at a visual endpoint reading of 80% inhibition as compared to the growth control. Intralaboratory MICs between blinded pairs were in 97% agreement at a visual endpoint reading of 50% inhibition as compared to the growth control and 96% agreement at a visual endpoint reading of 80% inhibition as compared to the growth control. Data from this study support consideration of this method as an amendment to the NCCLS M38-A standard for the testing of dermatophytes.

There have been several multicenter studies involving filamentous fungi which have been used in the development of the National Committee for Clinical Laboratory Standards (NCCLS) *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi. Approved Standard M38-A* (8). However, the published document does not address the antifungal susceptibilities of dermatophytes such as *Trichophyton*, *Microsporum*, and *Epidermophyton* species. Earlier studies of dermatophyte susceptibility have compared various methods. Niewerth et al. (9) compared the agar macrodilution and broth microdilution methods, demonstrating consistently lower MICs with the microdilution method. These lower MICs were more in line with skin tissue levels achieved by usual treatment regimens. Granade and Artis (5) used standardized fragmented mycelia as an alternative to conidial suspensions to overcome the lack of conidiation in some dermatophyte strains. Fernandez-Torres et al. (4) compared two different conidial suspension concentrations in the broth microdilution method and found no difference in the resulting MICs. Clearly, development and standardization of a method to determine the susceptibility of dermatophytes are needed.

The purpose of this multicenter study was to determine the inter- and intralaboratory reproducibility of MIC testing of

common dermatophyte species such as *Trichophyton*, *Epidermophyton*, and *Microsporum*, using the microdilution method developed at the Center for Medical Mycology. In order to develop such a method, Norris et al. (10) initially established the optimal growth conditions for the most common dermatophyte strains. These included the use of RPMI 1640 as the growth medium and 35°C for 4 days as the optimal temperature and incubation time, respectively. However, one special problem posed by dermatophytes is that conidium formation by *Trichophyton rubrum* is very poor on standard fungal isolation media. Subsequently, Jessup et al. (6) established the use of oatmeal cereal agar as the optimal growth medium for inducing conidium formation in *T. rubrum* isolates.

The NCCLS M38-A standard for susceptibility testing of filamentous fungi describes both macro- and microdilution methodologies, and according to results achieved in the multicenter study of filamentous fungi by Espinel-Ingroff, (1), interlaboratory agreement was demonstrated by both macro- and microdilution methods. Therefore, for this study the microdilution method was chosen because of its greater ease of performance. The aim of this study was to validate this method as a prelude to inclusion as a reference method for determining the antifungal susceptibility of dermatophyte isolates.

MATERIALS AND METHODS

Study participants. The following laboratories participated in this interlaboratory study: Department of Health, State of New York, Albany; Medical College of Virginia/Virginia Commonwealth University, Richmond; Center for

* Corresponding author. Mailing address: Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH 44106-5028. Phone: (216) 844-8580. Fax: (216) 844-1076. E-mail: mag3@cwru.edu.

Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio; University of Iowa College of Medicine, Iowa City; University of Texas Health Science Center, Audie L. Murphy Memorial Veterans Hospital, San Antonio; and Centers for Disease Control and Prevention, Atlanta, Ga.

Study design. The six participating laboratories were supplied with frozen microtiter plates, prepared by Trek Diagnostics, Westlake, Ohio. These plates contained 10 serial dilutions of the antifungals used, prepared in RPMI 1640, as well as two rows of RPMI 1640 without antifungal agents, which acted as growth and sterility controls. The individual antifungal ranges used were as follows: ciclopirox, 0.06 to 32 $\mu\text{g/ml}$; fluconazole, 0.125 to 64 $\mu\text{g/ml}$; griseofulvin, 0.125 to 64 $\mu\text{g/ml}$; itraconazole, 0.001 to 0.5 $\mu\text{g/ml}$; posaconazole, 0.015 to 8.0 $\mu\text{g/ml}$; terbinafine, 0.001 to 0.5 $\mu\text{g/ml}$; and voriconazole, 0.001 to 0.5 $\mu\text{g/ml}$. Each well contained 100 μl of drug or RPMI 1640 alone. Ten-milliliter tubes of RPMI 1640 were also supplied for inoculum preparation.

Isolates. Isolates were chosen from the culture collection of clinical isolates maintained at the Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University. These isolates had originally been subcultured onto potato dextrose agar (PDA) slants, incubated at 30°C until luxuriant, and frozen at -80°C. Stored isolates were thawed and subcultured onto PDA plates, from which sets of new slants were prepared. Each laboratory was sent a set of five blinded pairs of five dermatophyte strains, including *T. rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, *Epidermophyton floccosum*, and *Microsporum canis*. Three *T. rubrum* strains for which terbinafine MICs were low were included, corresponding to the published MIC data by Osborne et al. (11) and Mukherjee et al. (7) that the majority of terbinafine MICs for *T. rubrum* wild-type strains were 0.004 and 0.002 $\mu\text{g/ml}$, respectively. Two *T. rubrum* strains for which MICs were elevated were also included.

Antifungal agents. Standard powders of seven antifungals were obtained from the respective manufacturers, including ciclopirox (Dermik/Aventis, Berwyn, Pa.), fluconazole (Pfizer, New York, N.Y.), griseofulvin (Sigma), itraconazole (Janssen, Titusville, N.J.), posaconazole (Schering-Plough Research Institute, Kenilworth, N.J.), terbinafine (Novartis, Basel, Switzerland), and voriconazole (Pfizer).

Susceptibility method. The method used to determine the antifungal susceptibilities of dermatophytes to these agents was based on the publications of Norris (10) and Jessup (6). Each dermatophyte isolate was subcultured onto PDA and incubated at 30°C for 4 to 5 days or until good conidiation was produced.

T. rubrum isolates were subcultured onto cereal (oatmeal) agar instead of PDA in order to induce conidium production. A suspension of conidia in sterile saline was made by gently swabbing the colony surface with a sterile swab. The suspension was allowed to settle for 5 to 10 min, and conidia were counted with a hemacytometer. (For *T. rubrum* strains, turbidity produced by transference of oatmeal agar precludes the use of McFarland standards.) Working suspensions of conidia were prepared in 10 ml of RPMI 1640 to a final concentration of 1×10^3 to 3×10^3 CFU/ml. Yeast controls, which included *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258, were subcultured onto PDA and incubated at 35°C for 24 h. Yeast inocula were prepared to a final concentration of 0.5×10^3 to 2.5×10^3 CFU/ml. Microtiter plates were removed from the freezer and allow to thaw. Each drug concentration well and growth control well was inoculated with 100 μl of cell suspension by using a multichannel pipette. The final volume in each well was 200 μl . Dermatophyte plates were incubated at 35°C for 4 days (yeast controls were incubated for 48 h.) Plates were examined visually for 50 and 80% growth inhibition as compared to the growth control. MIC results were recorded in micrograms per milliliter.

Data analysis. All reported results were included in the data analysis. The measurement of interlaboratory agreement for each isolate (*T. rubrum*, *T. mentagrophytes*, etc.) was determined as a percentage of endpoints within 1, 2, and 3 dilutions (e.g., 0.5, 1.0, and 2.0 $\mu\text{g/ml}$). Interlaboratory agreement for the entire group of isolates, as well as intralaboratory agreement of blinded pair test results, was similarly determined. Results were considered in agreement if they fell within 3 dilutions.

RESULTS

Table 1 shows the cumulative MIC data from all sites reported by individual drug. All six participants detected two pairs of terbinafine-resistant *T. rubrum* isolates (one site had an additional outlier). Two sites did not report MICs for four

TABLE 1. Cumulative MIC parameter data from all sites

Endpoint and antifungal	MIC ($\mu\text{g/ml}$) ^a			Mean
	Range	50%	90%	
50% inhibition				
Ciclopirox	0.06–2.0	1.0	1.0	0.96
Fluconazole	0.125– ≥ 64	1.0	8.0	4.09
Griseofulvin	0.125–64	0.125	0.5	0.86
Itraconazole	0.001–0.125	0.008	0.06	0.02
Posaconazole	0.015–0.125	0.015	0.03	0.03
Terbinafine	0.001– ≥ 0.5	0.008	0.03	0.05
Voriconazole	0.001–0.25	0.008	0.06	0.02
80% inhibition				
Ciclopirox	0.06–2.0	1.0	1.0	1.0
Fluconazole	0.125– ≥ 64	2.0	16.0	6.99
Griseofulvin	0.125– ≥ 64	0.125	0.5	0.93
Itraconazole	0.001–0.5	0.015	0.125	0.04
Posaconazole	0.015–0.25	0.015	0.06	0.04
Terbinafine	0.001– ≥ 0.5	0.008	0.03	0.06
Voriconazole	0.001– ≥ 0.5	0.015	0.06	0.03

^a 50% and 90%, MIC₅₀ and MIC₉₀, respectively.

isolates, either because of lack of conidiation, which occurred with *M. canis* subcultures in particular, or contamination.

When read at the 50% endpoint, the MICs at which 50 and 90% of the isolates tested are inhibited (MIC₅₀ and MIC₉₀, respectively) for all antifungals were within 1 dilution of those read at the 80% endpoint.

Table 2 summarizes the interlaboratory agreement of individual drugs. Interlaboratory agreement within 3 dilutions ranged from 92% (itraconazole) to 100% (voriconazole and posaconazole) at the 50% inhibition endpoint and 87.8% (fluconazole) to 99.3% (posaconazole) at the 80% inhibition endpoint.

Table 3 summarizes the intralaboratory agreement or reproducibility of MIC results of blinded pairs by individual drug. Intralaboratory agreement within 3 dilutions ranged from 93.9% (fluconazole) to 100% (posaconazole) at the 50% inhibition endpoint and 89% (fluconazole) to 100% (ciclopirox and posaconazole) at the 80% inhibition endpoint.

TABLE 2. Interlaboratory agreement summary

Endpoint and antifungal	% of total isolates within:		
	1 dilution	2 dilutions	3 dilutions
50% inhibition			
Ciclopirox	94.6	96.0	99.0
Fluconazole	67.6	82.1	93.6
Griseofulvin	96.9	98.6	98.6
Itraconazole	63.9	79.8	92.0
Posaconazole	93.6	99.4	100
Terbinafine	84.5	92.9	98.0
Voriconazole	75.3	87.8	100
80% inhibition			
Ciclopirox	95.9	97.6	99.0
Fluconazole	64.9	85.8	87.8
Griseofulvin	88.9	97.7	98.4
Itraconazole	62.8	82.7	90.5
Posaconazole	88.8	95.6	99.3
Terbinafine	85.8	95.3	98.0
Voriconazole	73.6	89.1	97.5

TABLE 3. Intralaboratory agreement summary

Endpoint and antifungal	% of total isolates within:		
	1 dilution	2 dilutions	3 dilutions
50% inhibition			
Ciclopirox	91.8	96.6	99.3
Fluconazole	79.6	87.8	93.9
Griseofulvin	91.2	97.3	98.0
Itraconazole	73.5	86.4	95.2
Posaconazole	95.2	98.6	100
Terbinafine	84.4	91.2	97.3
Voriconazole	74.1	86.3	94.5
80% inhibition			
Ciclopirox	92.5	100	100
Fluconazole	74.8	83.6	89.0
Griseofulvin	91.8	96.6	98.3
Itraconazole	66.7	85.1	91.9
Posaconazole	89.8	97.3	100
Terbinafine	83.7	91.2	96.0
Voriconazole	74.1	87.4	96.2

DISCUSSION

Previously, griseofulvin had been the only antifungal available for the treatment of dermatophytoses. Recently, new antifungals have been developed that have activity against dermatophytes, and a reliable susceptibility testing method is needed to help physicians manage patients with dermatophyte infections. To this end, we designed a susceptibility method for dermatophyte isolates by first establishing the optimal growth conditions, including medium, temperature, and incubation time (6, 10). The current multicenter study was conducted as a prelude to the inclusion of this method as an NCCLS standard.

When establishing a susceptibility testing method, it is imperative to ensure reproducibility of endpoints and detection of resistance. Several previous multicenter studies have been conducted to establish guidelines for the susceptibility testing of yeasts and filamentous fungi (2, 3, 12, 13). The results from our study are similar to those obtained in those previous studies, which were subsequently used to establish approved standards.

In the present study, reproducibility of MIC endpoints was very high by both inter- and intralaboratory comparison. Lower percentages of agreement within 3 dilutions were achieved with fluconazole and itraconazole, although none were less than 87%. Since no significant differences were seen between 50 and 80% inhibition endpoints, we recommend the 80% inhibition endpoint for ease of interpretation. Importantly, all sites were able to detect resistance in the two pairs of terbinafine-resistant *T. rubrum* isolates provided.

Based upon the results of this multicenter study, adoption of this method as an amendment to the NCCLS M38-A standard for the testing of dermatophytes is warranted. Correlation of in vitro dermatophyte MICs with clinical outcomes, as well as establishing quality control strains, remains to be determined.

ACKNOWLEDGMENTS

The Center for Medical Mycology thanks Dermik Laboratories, Pfizer, Inc., and Schering-Plough Research Institute for their generous support of this study.

REFERENCES

1. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. *Antimicrob. Agents Chemother.* **39**:314-319.
2. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. *J. Clin. Microbiol.* **35**:139-143.
3. Espinel-Ingroff, A., M. Bartlett, V. Chaturvedi, M. Ghannoum, K. C. Hazen, M. A. Pfaller, M. Rinaldi, and T. J. Walsh. 2001. Optimal susceptibility testing conditions for detection of azole resistance in *Aspergillus* spp.: NCCLS collaborative evaluation. *Antimicrob. Agents Chemother.* **45**:1828-1835.
4. Fernandez-Torres, B., H. Vazquez-Veiga, X. Llovo, M. Pereiro, and J. Guarro. 2000. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole, and terbinafine of 100 isolates of *Trichophyton rubrum*. *Chemotherapy* **46**:390-394.
5. Granade, T. C., and W. M. Artis. 1980. Antimycotic susceptibility testing of dermatophytes in microcultures with a standardized fragmented mycelial inoculum. *Antimicrob. Agents Chemother.* **17**:725-729.
6. Jessup, C. J., J. Warner, N. Isham, I. Hasan, and M. A. Ghannoum. 2000. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. *J. Clin. Microbiol.* **38**:341-344.
7. Mukherjee, P. K., S. D. Leidich, N. Isham, I. Leitner, N. S. Ryder, and M. A. Ghannoum. 2003. Clinical *Trichophyton rubrum* strain exhibiting primary resistance to terbinafine. *Antimicrob. Agents Chemother.* **47**:82-86.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Niewerth, M., V. Splanemann, H. C. Korting, J. Ring, and D. Abeck. 1998. Antimicrobial susceptibility testing of dermatophytes—comparison of the agar macrodilution and broth microdilution tests. *Chemotherapy* **44**:31-35.
10. Norris, H. A., B. E. Elewski, and M. A. Ghannoum. 2000. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. *J. Am. Acad. Dermatol.* **40**:S9-S13.
11. Osborne, C. S., B. Hofbauer, B. Favre, and N. S. Ryder. 2003. In vitro analysis of the ability of *Trichophyton rubrum* to become resistant to terbinafine. *Antimicrob. Agents Chemother.* **47**:3634-3636.
12. Pfaller, M. A., M. G. Rinaldi, J. N. Galgiani, M. S. Bartlett, B. A. Body, A. Espinel-Ingroff, R. A. Fromtling, G. S. Hall, C. E. Hughes, F. C. Odds, and A. M. Sugar. 1990. Collaborative investigation of variables in susceptibility testing of yeasts. *Antimicrob. Agents Chemother.* **34**:1648-1654.
13. Pfaller, M. A., Q. Vu, M. Lancaster, A. Espinel-Ingroff, A. Fothergill, C. Grant, M. R. McGinnis, L. Pasarell, M. G. Rinaldi, and L. Steele-Moore. 1994. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. *J. Clin. Microbiol.* **32**:1625-1628.